Market Research Blog – Page 1664 – New Product Development

Peptide Receptor Radionuclide Therapy (PRRT) Market is Expected to Grow at an Outstanding CAGR of 8.2% to Reach USD 1.3 Billion by 2033 | FMI

The landscape of cancer treatment is undergoing a transformative shift, with the Peptide Receptor Radionuclide Therapy (PRRT) Market emerging as a powerful tool. The global PRRT market is poised for exceptional growth, with projections indicating a valuation of USD 591.83 million in 2023. This figure is set to skyrocket to a staggering USD 1.3 billion by 2033, driven by a robust Compound Annual Growth Rate (CAGR) of 8.2% during the forecast period.

Key Market Trends and Highlights

In this dynamic landscape, several trends and highlights are contributing to PRRT’s burgeoning success:

Innovative PRRT Approaches: Novel PRRT methods, including combination therapies and alternative radionuclides, are garnering significant attention for their enhanced effectiveness.
Enhanced Patient Selection: Improved diagnostic tools are revolutionizing the selection of patients and treatment planning, thereby optimizing PRRT outcomes.
The Power of Data Analytics and AI: Data analytics and artificial intelligence (AI) are playing a pivotal role in the customization of treatments, offering more effective and personalized patient care strategies.
Telemedicine Revolution: PRRT consultations and follow-ups are increasingly being conducted via telemedicine, enhancing accessibility and patient engagement.
Patient Advocacy for Positive Impact: The influence of growing patient advocacy groups is a driving force behind raising awareness, shaping policy, and advancing research, all of which are positively impacting the PRRT landscape.

Request a Sample Copy of This Report Now.

Advancement and growing researches in the medical industry leads to a dramatic surge in the availability of new cancer treatment options. Radiation therapies and targeted therapy is showing significant promise in cancer treatment. For example, peptide receptor radionuclide therapy (PRRT) had recently approved the neuroendocrine tumors and projecting significant growth in the cancer treatment market. Peptide receptor radionuclide therapy (PRRT) is radioisotope or molecular therapy used to treat neuroendocrine tumors (NETs).

Peptide receptor radionuclide therapy (PRRT) is recommended for the somatostatin receptor-positive gastroenteropancreatic NETs affected patients. Peptide receptor radionuclide therapy (PRRT) is a targeted therapy designed to slow the progression of gastroenteropancreatic NET and limiting radiation exposure to healthy tissue. Lutathera (lutetium Lu 177 Oxodotreotide) was the first drug approved for the peptide receptor radionuclide therapy (PRRT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In September 2017, the European Commission approved Lutathera peptide receptor radionuclide therapy (PRRT) drug manufactured by Advanced Accelerator Applications S.A. Although, the U.S. Food and Drug Administration (FDA) was approved LUTATHERA in January 2018. Growing clinical trials and development activities to create therapeutic radiopharmaceuticals expected to surge the growth of the peptide receptor radionuclide therapy (PRRT) market over the forecast period.

Peptide Receptor Radionuclide Therapy (PRRT) Market: Drivers and Restraints–

Increasing prevalence of the neuroendocrine tumors expected to impel the demand for peptide receptor radionuclide therapy (PRRT) as an increasing number of the patient pool. Establishment of reimbursement policies for Lutathera favors the demand for peptide receptor radionuclide therapy (PRRT). A temporary insurance/billing code was used for the peptide receptor radionuclide therapy (PRRT) till 2018. Moreover, increasing clinical trials for the new radiopharmaceuticals drugs approval for cancer therapy expected to surge the growth of the peptide receptor radionuclide therapy (PRRT) market.

Increasing government and private organizations funding for cancer drugs and therapy development is another major factor expected to propel the growth of the peptide receptor radionuclide therapy (PRRT) market. Moreover, growing manufacturer’s interest in the radiopharmaceutical and cancer market flourish the growth of the peptide receptor radionuclide therapy (PRRT) market. Side effects such as the transient decrease in blood counts, nausea and others associated with PRRT expected to hamper the growth of the peptide receptor radionuclide therapy (PRRT) market.

Peptide Receptor Radionuclide Therapy (PRRT) Market: Overview

Peptide receptor radionuclide therapy (PRRT) a special type of radiopharmaceutical which injected into the patients’ bloodstream. This radiopeptide travels and binds to neuroendocrine tumor cells and provide a high dose of radiation directly to the cancer cell. Big pharmaceutical market players are focusing to enter in the radiopharmaceutical market. For instance, In October 2017, Novartis AG acquired Advanced Accelerator Applications (AAA) for $3.9 billion to expand oncology portfolio. This acquisition was valuable for Lutathera radiopharmaceutical candidates which were under FDA review in 2018.

Peptide Receptor Radionuclide Therapy (PRRT) Market: Region-wise Outlook

North America and Europe region are expected to grebe more than half of the market share for peptide receptor radionuclide therapy. Increasing clinical trials for radiopharmaceuticals and growing demand for the targeted therapy for cancer are the major factors driving the growth of the peptide receptor radionuclide therapy market in the U.S. and European countries. The Asia pacific peptide receptor radionuclide therapy market expected to grow with significant growth rate as growing demand for advance treatment option and comparatively high prevalence of cancer in India and China.

Access Exclusive Market Insights – Purchase Now!

Key companies profiled:

Advanced Accelerator Applications (AAA) (Novartis AG)

Segments covered:

Indication,
End User,
Region

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Next Generation Infusion Pump Market is Expected to Grow at a 4.8% CAGR and Reach USD 8509 Million by 2032 | According to FMI Analysis

The healthcare landscape is undergoing a transformation, and the Next Generation Infusion Pump Market is at the forefront of this change. According to a recent analysis, the global market is expected to reach a substantial USD 8.5 billion by 2032, from a current value of USD 5059.7 million in 2022. This represents a steady Compound Annual Growth Rate (CAGR) of 4.8% during the forecast period (2022-2032).

Next Generation Infusion Pumps are a combination of intuitive user interface, simplicity, and state-of-the-art information technology. They are inclined with an advanced pumping system that measures flow to improve workflow efficiency and patient safety. Its smartphone-like user interface is designed to diminish interpretation and programming errors empowering end users to save time and reduction in pump interactions. Next Generation Infusion Pumps are largely accepted by healthcare professionals because they provide more patient safety and efficacy.

The technology used in regular infusion pumps hasn’t kept pace with advancements in the healthcare industry. According to a report published by the institute of Medicine in 2007, from the year 2005 to 2009, 710 deaths and more than 56,000 adverse events were reported to the FDA, most amongst medical technologies, adding more than $2 Bn to annual healthcare costs in the US. On the other hand, Next Generation Infusion Pumps provide enough functionality, flexibility, scalability, affordability, and ease of use needed for the changing needs of the healthcare system, indicating robust growth in the Next Generation Infusion Pump market over the forecast period.

Claim your complimentary report with captivating visuals.
https://www.futuremarketinsights.com/reports/sample/rep-gb-4131

Next Generation Infusion Pumps attribute high integration between the pump and hospital IT system, reducing errors. Moreover, diverse new technologies like implantable insulin pumps in addition to delivering targeted, consistent medication, increase patient ease as well. The leading market players are focusing on safer operability, minimized chances of product recalls, and enhanced product designs, over the forecast period.

Next Generation Infusion Pump Market: Drivers and Restraints

Insulin infusion pumps are dominating the Next Generation Infusion Pump market, however, worldwide booming prevalence of diabetes is a key driver for the Next Generation Infusion Pump market. Increased R&D initiatives on IV drug administration for malnutrition, cancers, diabetes, AIDS, neurological disorders, and gastrointestinal disorders coupled with technological innovation, are anticipated to generate lucrative growth in the Next Generation Infusion Pump market.

The regular infusion pump market has observed massive bad press in the last few years, for diverse risks and concerns over infusion errors, this restraint, however, has opened multiple opportunities for Next Generation Infusion Pump manufacturers. Furthermore, the lack of sufficient healthcare infrastructure in developing markets is anticipated to impact negatively on the Next Generation Infusion Pump market.

Next Generation Infusion Pump Market: Overview

Next Generation Infusion Pump market is emerging owing to the promising discovery of new innovative pumps. Key players in the market are focusing on new technologies such as smartphone-connected insulin pumps, wearable insulin pumps, and implantable insulin pumps, also focusing on accessing secure and immediate access to patient-specific infusion pump management information from any mobile device or computer, regardless of Electronic Medical Record integration. Such R&D improvements are making a ground-breaking infusion management platform, indicating transformation in Next next-generation Infusion Pump Market.

Next Generation Infusion Pump Market: Region-wise Outlook

Geographically, the next-generation infusion pump market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Europe regions are anticipated to contribute the maximum market revenue share in Next generation infusion pump market over the forecast period due to the availability of advanced healthcare infrastructure and the presence of key players in the regions which are expected to surge the demand for next-generation infusion pumps during the forecast period in the above-mentioned region. Asia Pacific region as well, is anticipated to witness crucial growth due to growing healthcare infrastructure in the region. An increasing number of mid-sized hospitals is identified to be a major driver of the APEJ market growth.

Next Generation Infusion Pump Market: Key Players

The players leading in next next-generation infusion pump market include Ivenix, Inc., Zyno Medical, B. Braun Melsungen AG, Baxter International, Inc., F. Hoffmann-la Roche Ltd., Johnson & Johnson (U.S.), Pfizer (Hospira) Inc., and Smiths Medical to name a few.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology, and applications.

Tap into Comprehensive Segmented Information – Purchase Now!
https://www.futuremarketinsights.com/checkout/4131

The report covers an exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico, Brazil, and Rest of Latin America)
Western Europe (Germany, Italy, France, UK, Spain, Nordic countries, Belgium, Netherlands, Luxembourg, and the Rest of Western Europe)
Eastern Europe (Poland, Russia and Rest of Eastern Europe)
Asia Pacific (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, and Rest of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Next Generation Infusion Pump Market: Segmentation

Based on Application

Oncology
Analgesia
Diabetes
Hematology
Neonatology
Gastroenterology
Autoimmune Diseases

Based on end users

Hospitals
Ambulatory Surgical Centers (ASCs)
Clinics
Others

Report Highlights:

Detailed overview of the parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current, and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Deception Technology Market to Surge to $6.7 Billion by 2033, Growing at a 12.6% CAGR

The market for deception technology is estimated to reach $2 billion in value by 2023. It is expected to grow to US$ 6.7 billion by 2033, reflecting a 12.6% CAGR between 2023 and 2033. During the same time span, the market might have a US$ 4.7 billion absolute dollar potential.

Because cyber threats are continuously growing, security techniques must evolve as well. Antivirus software and firewalls, which were formerly sufficient for security, are no longer effective against today’s sophisticated attacks.

By setting up a network of deceptive traps and decoys that detect and divert intruders, deception technology provides a proactive security mechanism. This novel strategy is expected to add an extra degree of protection for enterprises. As a result, it would be a desirable approach to counter new cyber threats.

Request a Sample of this Report:

Ability of an organization to identify and react is improved by deception technology. Organizations can divert attackers away from vital assets by using realistic decoys. Additionally, they can learn crucial information about their strategies, methods, and objectives.

Early detection enables quick response and correction, reducing the potential harm brought on by cyberattacks. Ability to proactively identify risks and take appropriate action is a key factor driving demand for deception technologies.

Organizations might also be at danger from insider threats. Hence, it is essential to put precautions in place to lessen this risk. By constructing decoys and traps that are only visible to insiders, deception technology can be important in combating insider threats.

The strategy enables businesses to spot dishonest insiders or compromised accounts and take the necessary countermeasures. Deception technology will offer enterprises improved security and peace of mind by giving them a proactive way to identify and stop internal threats.

Demand for deception technologies would also be significantly influenced by compliance and regulatory needs. Strict data protection and security laws apply to a number of sectors, including healthcare, finance, and government.

Deception technology offers an advanced security solution that goes beyond fundamental compliance measures, assisting enterprises in meeting these criteria. Organizations might be sure they are adhering to legal requirements and avoiding penalties by exhibiting proactive security measures.

Corporations might also find deception technology to be a cost-effective security measure. Without making substantial investments in extra hardware, businesses can increase security by strategically installing decoys and traps. This makes the cost of developing deception technologies a viable investment.

Due to the sensitivity or importance of their intellectual property, certain sectors such as defense, critical infrastructure, and high-tech manufacturing, have specific security requirements. Deception technology provides specialized answers to handle these particular challenges. Hence, it might offer specialized decoys and traps that correspond with threats and attack vectors that are unique to a given sector.

Key Takeaways from Deception Technology Market Study:

China deception technology industry is projected to witness a CAGR of 5% from 2023 to 2033.
The United States deception technology industry witnessed a CAGR of 1% in the historical period.
The United Kingdom deception technology industry is anticipated to surpass a valuation of US$ 264 million by 2033.
By offering, the solution segment showcased a CAGR of 0% in the historical period.
By deception stack, the network security segment is predicted to witness 2% CAGR from 2023 to 2033.

Engage in a conversation with our research expert to delve deeper into the subject and gain valuable insights for your specific needs:

“Across several sectors, compliance rules have tightened, necessitating strong security measures. These needs are met by deception technology, which offers proactive security measures and improves threat detection capabilities. It is further expected to open door to new opportunities in the market.” – Says a lead analyst at Future Market Insights (FMI).

Competitive Landscape

The deception technology market’s competitive environment is dynamic and ever-changing. There are a variety of established businesses, new start-ups, and providers of specialized solutions in the market.

Several well-known businesses have emerged as market leaders in the field of deception technology. These businesses have a significant market presence, a sizable customer base, and a broad portfolio of deception technologies.

They frequently have a history of effective deployments and collaborations with other cybersecurity firms. To remain ahead of new threats and continuously enhance their products, market leaders often make significant investments in research & development.

The deception technology sector is heavily reliant on collaboration and strategic alliances. To increase their reach, businesses frequently form agreements with other cybersecurity vendors, managed security service providers, or system integrators.

They also want to increase the number of clients they serve and provide all-inclusive services. Through the harnessing of synergies and the pooling of capabilities, partnerships can increase market competitiveness.

For instance,

The Cybersecurity & Infrastructure Security Agency (CISA), a division of the Department of Homeland Security, announced in April 2022 that its FedRamp Ready ShadowPlex platform had been included. Acalvio Technologies is a pioneer in the field of cyber deception. The business would be able to use and acquire cutting-edge deception technology with the addition of this platform. Additionally, the platform would aid them in thwarting sophisticated foes.

Experience data freedom – Discover Report Customization today!

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

New Born Eye Imaging Systems Market is expected to reach USD 374.3 Million by 2032, With a 5.7% CAGR | FMI

The health and development of newborns are a top priority, and advancements in eye imaging technology are playing a critical role. The global New Born Eye Imaging Systems Market is poised for growth, with a projected value of USD 374.3 million by 2032. This represents a significant increase from the current market value of USD 202.7 million in 2022, reflecting a Compound Annual Growth Rate (CAGR) of 5.7% during this period.

The eye is the most complex sensory organ of the body, the eye is like a camera of higher resolution for capturing images, it works in a very simple process as light is focused on the eye cornea which is the lens of the eye, iris controlled the intensity of light, then the light fall on the retina for image formation then the signal generated from retain is passed through the optic nerve to the brain that controls the sense of sight.

The eye imaging system is a tool used for identifying the problem for treatment. Ophthalmic is related to the eye, major the population is suffering from eye disorders. As in newborn babies, the ROP (Retinopathy of Prematurity) is the main reason for vision loss, ROP also affects the blood vessels and spreads via the retina.

New Born Eye Imaging Systems: Drivers and Restraints

Newborn eye imaging is an emerging market, as many players are coming up with innovative devices for imaging and raising funds for research on newborn eye imaging systems, for instance, in May 2017, Visunex Medical Systems, Inc., raised a fund of USD 20 Mn for the research and development and manufacturing of newborn eye imaging system. Players are actively participating in the development of imaging systems.

Click here to claim your report with captivating visuals.

The ratio of affected babies also fuels the market to come up with more advanced products in the market, for instance, according to WebMD, LLC., 16,000 out of 28,000 born babies are affected by ROP (retinopathy of prematurity) as the babies will be born less than 31 weeks and the weight will be more than 2 pounds in the U.S, The awareness is the hindrance for the product.

New Born Eye Imaging Systems: Overview

Newborn eye imaging systems is a growing market over the forecast period, as many products are coming into the market after getting approval from respective organizations, all the products are in high demand for imaging, for instance, in March 2012, Russia’s third president has approved the purchase of newborn eye imaging system from Clarity Medical Systems, Inc., and launched RetCam digital imaging program in Russian Federation for the treatment of prematurely born infants at risk for eye diseases like ROP (retinopathy of prematurity).

New Born Eye Imaging Systems: Region-wise Outlook

Geographically, the New Born Eye Imaging Systems Market is segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, Japan, the Middle East, and Africa.

North America is the leading market as major players are placed inside and the number of population is effected by new eye problems, for instance, according to the Centers for Disease Control and Prevention in October 2016, one in every 33 babies is affected by eye-borne diseases. Europe is also a potential market as governments are directly involved in the treatment of eye diseases. Asia Pacific is a growing market as the awareness is very low in the market about this system.

New Born Eye Imaging Systems: Key Players

Some players in the New Born Eye Imaging Systems Market include Visunex Medical Systems, Inc., Eye Photo Systems, Merge Healthcare Incorporated, D-EYE S.r.l., Imagine Eyes, Natus Medical Incorporated, and Servicom Medical (Singapore) Pte Ltd.

The report covers an exhaustive analysis on

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

Get Ahead with Comprehensive Information – Purchase Now!

Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico, Brazil, and the Rest of Latin America)
Western Europe (Germany, Italy, France, UK, Spain, Nordic countries, Belgium, Netherlands, Luxembourg, and the Rest of Western Europe)
Eastern Europe (Poland, Russia and Rest of Eastern Europe)
Asia Pacific (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, and Rest of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

New Born Eye Imaging Systems Market: Segmentation

Based on disease type

Retinopathy of prematurity
Ocular development
Refractive state
Strabismus
Visual functions
Visual acuity
Visual fields
Color vision

Based on Device Type

Basic Device
Wireless Device

Based on End User

Hospital
Ophthalmology Diagnosis Centre
Ambulatory Surgical Centre
Others

About Future Market Insights (FMI)

Contact Us:

Pulmonary Fibrosis Biomarkers Market Set for Significant Growth, Expected to Reach USD 6,538.4 Million by 2034 at a 4.4% of CAGR

The global pulmonary fibrosis biomarkers market is on a strong upward trajectory, with projections indicating an increase from USD 4,353.0 million in 2024 to USD 6,538.4 million by 2034. This anticipated growth reflects a compound annual growth rate (CAGR) of 4.4% over the next decade, building on a valuation of USD 4,149.0 million in 2023.

The market expansion is driven by advancements in pulmonary fibrosis biomarkers, which are making it easier to discover, validate, and integrate new biomarkers into clinical practice. These developments are pivotal in improving the diagnosis and management of pulmonary fibrosis, a chronic and progressive lung disease.

Key factors contributing to market growth include the application of bioinformatics tools and the advancement of high-throughput screening techniques. These innovations enhance the ability to identify and analyze biomarkers with greater precision, leading to more effective and targeted treatments for pulmonary fibrosis.

Get your PDF – Sample Report

The market for pulmonary fibrosis biomarkers is expected to rise, which highlights how the field of pulmonary fibrosis research and clinical practice is changing. Dependable biomarkers will be in greater demand as the prevalence of pulmonary fibrosis rises, driven by factors including aging populations and environmental exposures.

Pulmonary fibrosis biomarkers are crucial for monitoring therapy response and disease activity because they enable clinicians to assess the effectiveness of medications, modify course, and monitor the disease over time. Maintaining patient care and evaluating the efficacy of treatment need long-term monitoring.

Key Takeaways:

Accelerated Growth: Sales of pulmonary fibrosis biomarkers are projected to accelerate at a CAGR of 4.4% from 2024 to 2034, indicating robust market expansion.
Market Projection: The market is expected to increase from US$ 4,353.0 million in 2024 to US$ 6,538.4 million by 2034, reflecting growing demand and advancements in biomarker technologies.
Critical Role: Pulmonary fibrosis biomarkers play a vital role in the diagnosis, prognosis, and treatment monitoring of pulmonary fibrosis, contributing to improved patient outcomes and quality of life.

Customization Available – Here

Competitive Landscape:

Key pulmonary fibrosis biomarker manufacturers significantly shape the sector’s competitive landscape. Known for its dedication to innovation, Biogen welcomes Veracyte, which is one of the significant pulmonary fibrosis biomarker providers, emphasizing cutting-edge diagnostic solutions.

Galapagos NV offers its advantages to the market, while Genentech, a Roche company, adds its pharmaceutical knowledge. Biocartis and Myriad Genetics are essential in pulmonary fibrosis biomarkers since they offer specific solutions.

These key pulmonary fibrosis biomarker vendors work together to enhance research and development, which supports the market’s general expansion and development for pulmonary fibrosis biomarkers. Their combined efforts highlight the pulmonary fibrosis biomarker industry’s dynamic nature as it continues to tackle the difficulties related to pulmonary fibrosis.

Latest Advancements:

To provide Oklahomans with the newest diagnostic and therapeutic equipment, O.U. Health, a comprehensive academic health system, and Siemens Healthineers, a leader in medical technology, announced a strategic 10-year value partnership in December 2023.
Thermo Fisher Scientific and AstraZeneca collaborated in January 2023 to create a companion diagnostic test for Tagrisso based on solid tissue and blood. With its global presence, Thermo Fisher Scientific can service a wide range of clients and take advantage of expansion prospects worldwide.
A deal to buy all of the outstanding shares of Curiosity Diagnostics from Scope Fluidics, S.A., was announced by Bio-Rad Laboratories, Inc. in August 2022. The deal could be worth up to US$ 170 million, with roughly US$ 100 million going toward cash and another US$ 70 million coming from future milestone payments.
Biogen Inc. agreed to pay a total of US$ 900 million in September 2022 to settle allegations that it gave doctors payments to persuade them to prescribe Biogen drugs, which resulted in the doctors making false claims with Medicare and Medicaid.

Key Players:

Biogen
Veracyte
Genentech (Roche)
Galapagos NV
Biocartis
Myriad Genetics

Key Developments in the Pulmonary Fibrosis Biomarkers Market:

In September 2022, Biogen Inc. has consented to pay a total of US$ 900 million to resolve claim that it paid kickbacks to doctors to encourage them to prescribe Biogen medications, which led to the filing of false claims with Medicare and Medicaid.

Segmentation Analysis of the Pulmonary Fibrosis Biomarkers Market:

By Test Type:

HRCT Scans
X-Ray Scans
Lung Biopsy
Blood Tests
Pulmonary Function Tests

By End User:

Diagnostic Laboratories
Academic and Research Institutes
Hospital Laboratories
Biopharmaceutical Companies
Others

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
The Middle East & Africa

Secure Your Market Analysis Now – Purchase Now to Access

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Myelodysplastic Syndrome Treatment Market is expected to reach USD 5,614.1 Million by 2032, with a CAGR of 5.9% | FMI Study

The fight against myelodysplastic syndrome (MDS) is gaining momentum, with the global Myelodysplastic Syndrome Treatment Market poised for significant growth. According to a recent analysis, the market is set to capture a revenue share of USD 2,990.8 million in 2022 and is projected to reach a substantial USD 5,614.1 million by 2032. This translates to a steady Compound Annual Growth Rate (CAGR) of 5.9% over the next decade.

Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow are damaged. This damage leads to low numbers of one or more types of blood cells. MDS is considered as a type of cancer.

Myelodysplastic syndromes are a rare group of disorders in which the body no longer makes enough healthy blood cells. This disorder can also be called “bone marrow failure disorder.”

Claim your complimentary report with captivating visuals.

The patient pool is more of an age group of 50 or older, but it can happen to younger people, too. This syndrome is more common in men as compared to women.

According to the American Society of Clinical Oncology (ASCO), approximately 13,000 people in the U.S. are diagnosed with MDS each year.

Myelodysplastic Syndrome Treatment Market: Drivers and Restraints

The Myelodysplastic Syndrome Treatment market is expected to mark a significant growth in the coming few years due to increasing mutation in treatments which cause myelodysplastic syndrome. In addition to this, the growing number of patient pool of age 50 and above, and rising government support for cancer treatment tend to propel the market.

However, unawareness about such treatments is one of the major factors that is delaying the growth of this market.

Myelodysplastic Syndrome Treatment Market: Overview

The global market for myelodysplastic syndrome treatment is expected to witness high growth over the forecast period due to increasing incidences of myelodysplastic syndrome. In the U.S., myelodysplastic syndromes (MDS) occur at a rate of 4.8 cases for every 100,000 people. That works out to about 13,000 new cases of MDS each year. The number of new cases diagnosed each year seems to be increasing as the average age of the population increases. (Source: American Cancer Society).

Furthermore, diagnosis techniques such as blood count, peripheral blood smear test, microscopic exams, cytochemistry, flow cytometry and immunotherapy, cytogenetics, FISH, and PCR help in the detection of MDS, also a key factor that is propelling the myelodysplastic syndrome treatment market towards growth.

Myelodysplastic Syndrome Treatment Market: Regional Outlook

Geographically, the global myelodysplastic syndrome treatment market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America and Europe together dominate the global myelodysplastic syndrome treatment market due to the presence of a large population suffering from bone marrow disease, a rise in healthcare expenditure, and increasing demand for myelodysplastic syndrome treatment by the end users. Asia Pacific’s myelodysplastic syndrome treatment market is expected to be one of the fastest growing markets due to the increasing number of patients with blood marrow disorders.

Myelodysplastic Syndrome Treatment Market: Key Players

The market for myelodysplastic syndrome treatment is consolidated with the presence of a few strong players. Some of the players identified in the global myelodysplastic syndrome treatment market include Celgene Corporation, Otsuka Holdings Co., Ltd., Sandoz, Inc., Dr. Reddy’s Laboratories, Inc., Accord Healthcare Ltd., Mylan N.V., Pfizer, Inc., etc.

The report is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers an exhaustive analysis on

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Value Chain

Gain the Edge with Segmented Information – Buy Now!

Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
Eastern Europe (Russia, Poland, Rest of Eastern Europe)
Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
Japan
The Middle East and Africa (GCC, South Africa, Rest of MEA)

Myelodysplastic Syndrome Treatment Market: Segmentation

Tentatively, the global myelodysplastic syndrome treatment market has been segmented based on types, treatments, patient groups, and geography

Based on Type

Refractory cytopenia with unilinear dysplasia (RCUD)
Refractory anemia with ringed sideroblasts (RARS)
Refractory cytopenia with multilineage dysplasia (RCMD)
Refractory anemia with excess blasts-1 (RAEB-1)
Refractory anemia with excess blasts-2 (RAEB-2)
Myelodysplastic syndrome, unclassified (MDS-U)
Myelodysplastic syndrome associated with isolated del(5q)

Based on treatment

Chemotherapy
Immunotherapy
Stem cell transplantation/bone marrow transplantation
Growth Factors

Based on the patient group

Above 50 years
Below 50 years

About Future Market Insights (FMI)

Contact Us:

Thin Film and Printed Batteries Market to Soar from $180.78 Million in 2023 to $1,138.14 Million by 2033 at a CAGR of 20.2%

According to predictions, the Thin Film and Printed Batteries Market will be worth US$ 180.78 million in 2023 and $1,138.14 million in 2033. Between 2023 and 2033, the market is expected to increase at a CAGR of 20.2%.

The density, longevity, and safety of thin film and printed batteries have increased. The growing demand for these batteries in electronic devices and medical equipment is driving big corporations to innovate, allowing batteries to become more flexible or smaller.

To address the shortcomings of solid-state batteries, Tokyo Tech Corporation and Tohoku University, for example, have produced batteries with lower resistance.

Market Opportunities

The development of IoT and wireless sensor technologies has led to a rapid uptake of wireless sensors worldwide.
Wireless sensors are now being employed in situations where they have not before been used due to the rapid development of energy-harvesting technologies like thin film and printed flexible batteries.
Microbatteries’ excellent form factors, ultra-thin profiles, and minimal leakage characteristics make it possible to capture energy. Thin film and printed battery manufacturers anticipate the rising popularity of energy-harvesting-based autonomous wireless sensors to provide new business opportunities.

Explore the Booming Thin Film and Printed Batteries Market with Our Sample Report!

Key Takeaways from Thin Film and Printed Batteries Market Report:

By 2033, the thin films and printed batteries market in the United Kingdom is likely to expand, with a CAGR of 19.3%.
By 2033, the United States is expected to dominate the thin films and printed batteries market with a valuation of US$ 325.6 million.
The thin films and printed batteries market was significantly expanding, with a size of US$ 150.4 million in 2022.
The thin films and printed batteries sector expanded at a CAGR of 24.3% from 2018 to 2022.
By 2033, China’s thin films and printed batteries market is projected to expand, with a CAGR of 21.3%.
By 2033, South Korea is expected to expand significantly in the thin films and printed batteries business, with a CAGR of 20.7%.
Japan’s thin films and printed batteries industry is likely to expand significantly, with a 19.6% CAGR by 2033.
By 2033, the below 1.5 V segment is expected to dominate the market, with a CAGR of 20.1%, based on voltage.
By 2033, the below 10 mAh segment is expected to dominate the market, with a CAGR of 20%, based on capacity.

Top Competitors and Their Winning Strategies

To improve their market positioning, makers of thin film and printed batteries have used various techniques, including new product introductions, product development, and acquisitions.

Samsung SDI Co., Ltd
Enfucell Oy Ltd.
Ultralife Corporation
Blue Spark Technologies
BrightVolt, Inc

Recent Developments:

In March 2020, Wearable Temperature Tag, a new product from Enfucell, was just introduced. The tag is built using a combination of SoftBattery, NFC, and a sophisticated temperature sensor.
With consistent investment in research and development, Samsung SDI secures breakthrough technologies and increases technological competitiveness. Moreover, Samsung SDI is taking a giant step toward the energy field by extending its business into the cutting-edge materials and components industry.
Imprint Energy said in August 2019 that the developer’s kit for their flexible, ultrathin, secure, printable batteries is now more widely available. The batteries were created specifically to power IoT devices integrated with Semtech’s LoRa devices for low power wide area networks and functioning with Bluetooth Low Energy and other standards.

Have questions about the report? We’re here to help! Get the clarity you need by asking us your questions about this valuable resource

Thin Film and Printed Batteries Market: Key Segmentation

By Type:

Thin Films Batteries
Printed Batteries

By Voltage:

Below 1.5V
Between 1.5V and 3V
Above 3V

By Capacity:

Below 10 mAh
Between 10 mAh and 100 mAh
Above 100 mAh

By Rechargeable:

Primary Batteries
Secondary Batteries

By Application:

Consumer Electronics
Smart Cards
Smart Packaging
Medical Devices
Wireless Sensors
Others

By Region:

North America
Latin America
Europe
East Asia
South Asia & Pacific

Request for Customization

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Preterm Birth Diagnostic Test Kit Market Poised for Significant Growth, Expected to Reach USD 316.5 Million by 2034 at a 7.6% of CAGR

The global preterm birth diagnostic test kit market is set for robust expansion, with forecasts estimating a rise from USD 152.2 million in 2024 to USD 316.5 million by 2034. This growth reflects a compound annual growth rate (CAGR) of 7.6% over the next decade.

In 2021, the preterm birth diagnostic test kit sector accounted for approximately 1% of the global rapid diagnostic test kit industry. Despite its current market share, the sector presents substantial growth opportunities, particularly in developing regions such as Asia Pacific, the Middle East, and Africa, where awareness and adoption of preterm diagnostic kits remain limited.

The increasing recognition of the importance of early detection and management of preterm births is expected to drive demand for diagnostic test kits. These kits play a crucial role in identifying risk factors and enabling timely interventions, thereby improving outcomes for both mothers and infants.

Get your PDF – Sample Report

One of the main factors propelling the market’s expansion is the increased public awareness of preterm birth difficulties and the need of early detection and intervention. It is projected that as healthcare systems around the world prioritize the health of women and infants and close critical gaps in prenatal care, the usage of preterm birth diagnostic test kits will increase dramatically.

The positive outlook for the worldwide market for preterm birth diagnostic test kits emphasizes how important it is for industry participants to keep coming up with new ideas, staying informed, and cooperating. As the industry grows, manufacturers, policymakers, and healthcare professionals will have a great chance to enhance prenatal care and reduce the number of premature births.

Key Findings Presented in the Report on the Preterm Birth Diagnostic Test Kits Market:

According to the data, the number of births in 2017 was roughly 115.4 million, of which 12.8 million or 11.1% were preterm. Preterm birth problems are the biggest cause of death for children under the age of five, according to the World Health Organization. In 2015, they were directly responsible for around one million deaths. Of these, cost-effective measures can avoid three-quarters of these deaths. Across different regions, preterm birth diagnostic test kit adoption rates varied from 2% to 15%. A substantial chunk of the preterm birth test kit market has gone untapped, leaving it open for manufacturers of preterm diagnostic test kits. This is because the majority of the current patient pool is ignorant of the cost-saving advantages of preterm birth diagnostic test kits.

Analysis of the Preterm Birth Diagnostic Test Kits Market:

The most common sample used for preterm labor and premature membrane rupture diagnosis in preterm birth diagnostic test kits is blood. The most popular and widely recognized preterm birth diagnostic test kits among end users are those that employ blood samples for preterm birth diagnosis. On the other hand, preterm birth diagnostic test kits using vaginal discharge sample type are becoming more and more common.

Patients experiencing symptoms of preterm birth are primarily referred to hospitals, outpatient clinics, and diagnostic laboratories that use preterm birth diagnostic tests. Because they are the principal healthcare institution for preterm cases, hospitals are expected to account for the majority of the revenue share under the end users segment for the preterm birth diagnostic test kits market in 2017.

Preterm Birth Diagnostic Test Kits Market – Competitive Landscape:

The key players of this market are adopting strategies such as product launch, acquisition, partnership and collaborations to gain expand their market presence and open up new streams of revenue generation.

In June 2021, Medix Biochemica announced the launch of a new molecular diagnostic reagents division named “MedixMDx” to offer extensive range of products and services for their customers.
In September 2020, QIAGEN announced the acquisition of NeuMoDx Molecular Inc., which helped the company to complete their product portfolio of PCR technology based automated molecular testing solutions.
In May 2021, Sera Prognostics announced a strategic commercial partnership with Anthem Inc., to make their “PreTRM® “tests available to all the customers of Anthem in the U.S.

Since the awareness of preterm birth diagnostic test kits is increasing, the demand for these kits will rise in the next few years. This creates many lucrative opportunities for the key players of this industry.

Unlock Tailored Insights – Customize Your Report for Maximum Impact

Key Companies Profiled:

Qiagen
Medix Biochemica
Hologic Inc.
Sera Prognostics
IQ Products
Creative Diagnostics
Nanjing Liming Biological Preparations Co., Ltd.
Clinical Innovations, LLC
Bioserv Diagnostic GmbH

Preterm Birth Diagnostic Test Kits Market, By Category:

Product:

ffN Test
PAMG-1 Test
IGFBP-1 Test

Sample:

Blood
Urine
Vaginal Discharge

End User:

Hospitals
Diagnostic Laboratories
Outpatient Clinics
Research Centers

Region:

North America
Latin America
Western Europe
Eastern Europe
Middle-East & Africa
APECJ
China
Japan

Secure Your Market Analysis Now – Purchase Now to Access

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Hybrid Grafts Market Is Anticipated to Expand at 5.20% CAGR to Reach USD 858.7 Million by 2032 | FMI Report

The global Hybrid Grafts Market is experiencing rapid growth, driven by the escalating prevalence of cardiovascular disease. According to recent market analysis, the market is valued at USD 517.3 million in 2022 and is projected to reach a substantial USD 858.7 million by 2032, with a Compound Annual Growth Rate (CAGR) of 5.20%. This significant expansion underscores the increasing demand for innovative solutions in cardiovascular surgery.

Infections caused by viruses can infect the inner surfaces of veins and arteries, resulting in blood clots, mild blood vessel damage, and inflammation of adjacent blood vessels. These factors have the potential to reduce blood flow to the heart and other organs, leading to an increase in cases of cardiovascular disease during the next decade. The number of cases of chronic ascending aortic dissection has also increased considerably globally, adding to market expansion.

Claim your complimentary report with captivating visuals.

Furthermore, prominent market participants are concentrating on developing novel products with increased efficacy, such as environmental stability, infection resistance, and durability. BD Interventional, for example, just launched Distaflo, which combines ePTFE with carbon soaked into the interior parts of the graft wall, as well as a patented cuff at the distal end.

Key Takeaways: Hybrid Grafts Market

The thoracic aortic graft segment represented roughly 78.2% of the market share in 2021 and is expected to dominate the global Hybrid Grafts market by 2032.
The hospital sector is estimated to lead the worldwide Hybrid Grafts market with a 5.9% CAGR during the forecast period.
The North American hybrid Grafts market is expected to generate 42.1% in 2021 and will continue to lead in the coming years.
With the expansion of the healthcare business, China is expected to hold a market share of almost 3.8% in 2032.
Germany’s Hybrid Grafts market held a 3.5% share in 2021 and is expected to remain at the forefront during the evaluation period.

“Rising use of minimally invasive devices in medical procedures is set to drive the Hybrid Grafts market. Besides, increasing number of cardiac and vascular surgeries is anticipated to push demand for Hybrid Grafts to reduce surgical site complications,” says a FMI analyst.

Hybrid Grafts Market Competition

The market for Hybrid Grafts is moderately fragmented and there exists a large number of local, emerging, as well as established players across the globe. Key players are initiating promotional activities to introduce new designs to attract more customers. A few other companies are engaging in collaborations and expansion activities to develop innovative products.

In October 2021, Terumo collaborated with Cell Technologies to construct a new production facility in Costa Rica, which will support the company’s global supply chain.
In May 2022, Getinge invested 3 million Euros to increase its capacity for producing polyester grafts and patches for the treatment of aneurysmal and occlusive illnesses. The investment would enable the company to increase manufacturing capacity at its La Ciotat, France, plant.

Key Players

Terumo Corporation
BD Interventional
Getinge AB
Merit Medical Systems, Inc.
JOTEC GmbH

Contact Sales for Further Assistance in Purchasing this Report!

More Valuable Insights on Hybrid Grafts Market

Future Market Insights offers a unique perspective and actionable insights on the Hybrid Grafts market in its latest study, presenting a historical demand assessment of 2017 to 2021 and projections for 2022 to 2032.

The research study is based on the product (thoracic aortic graft and peripheral vascular graft) and end-user (hospitals and ambulatory surgical centers), across seven key regions of the world.

Hybrid Grafts Market Outlook by Category

By Product:

Thoracic Aortic Graft
Peripheral Vascular Graft

By End User:

Hospitals
Ambulatory Surgical Centers

About Future Market Insights (FMI)

Contact Us:

Motorized Prosthesis Market is Expected to Reach USD 139.4 Million by 2032 at a 14.4% CAGR | FMI

The future of mobility is here, with the Motorized Prosthesis Market taking center stage. This innovative technology is transforming the lives of amputees, and the market is reflecting that change. According to a recent analysis, the global motorized prosthesis market is set to reach a significant USD 139.4 million by 2032, growing at a robust Compound Annual Growth Rate (CAGR) of 14.4% from its current valuation of USD 31.9 million in 2022.

The motorized prosthesis is an artificial medical device used to perform the functions of missing body parts due to factors such as trauma, congenital factors, or various other diseases. The concept of motorized prosthesis arises from the combination of biomedical engineering and neuroscience.

The motorized prosthesis is based on brain brain-computed interface, to avail the biological functioning of missing body parts. The motorized prosthesis is a complex network of motors and cognitive modalities. These devices are made for supporting of autonomous nervous system functioning such as devices for bladder control.

Claim your complimentary report with captivating visuals.

The motorized prostheses are in the research and development phase, and various technological advancements have been witnessed in developing a novelty product to support the normal functioning of the body. The motorized prostheses are based on target muscle innervation (TMR) technology.

Motorized Prosthesis Market: Overview

The motorized prosthesis market is an emerging technology and is adopted by a large number of affected patient population base. The motorized prosthesis is based on the integration with the nervous system to conduct the functioning of the replaced body part by a device known as a controller that maintains the compatibility between the patient’s nervous system and muscular systems.

Motorized prosthesis work by sending users’ commands to the device’s actuators, and deduces the feedback from the biosensors. Motorized hand prostheses are widely used as compared with motorized leg prostheses. Information technology also plays a crucial role in the development of motorized prostheses.

Various programs have been conducted such as open-source robotic prostheses through which various collaborations are made by players for bringing advancement in the technology coupled with lowering the cost of the devices by using 3D printing technology for custom-made fabrication.

Motorized Prosthesis Market: Region Wise Outlook

Geographically, the motorized prosthesis market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is projected to hold the largest share of motorized prostheses in the global market, followed by Western Europe, owing to more developed healthcare infrastructure and ease of access to advanced technology.

In addition, high disposable income, support from governmental bodies, and favorable reimbursement scenarios are driving the growth of the motorized prosthesis market. The market in Asia-Pacific is expected to show the fastest growth over the forecast period owing to the consistent technological advancement, and increasing R&D investment by the public and private bodies.

The market in regions such as Latin America, the Middle East, and Africa is anticipated to show sluggish growth owing to low per capita income, lack of skilled personnel, and limited medical facilities.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.

Motorized Prosthesis Market: Drivers and Restraints

The motorized prosthesis market is expected to show tremendous growth during the forecast period. Factors such as technological advancement in motorized prostheses, and increasing research and development expenditure to support the lives of affected patients are driving the growth of the motorized prosthesis market.

Increasing healthcare infrastructure along with the growth in IT infrastructure are also driving the growth of the motorized prosthesis market. In addition, according to research studies conducted, approximately 2 million individuals are living without a limb in the U.S. alone, and nearly 185,000 amputations occur in the U.S. every year.

However, the motor prosthesis is in its initial phase of development, and factors such as high developmental cost, and pricing are the major constraints of the motorized prosthesis market growth. The factors such as the modeling of the device, power consumption, size, and biocompatibility are major issues that can hamper the growth of the motorized prosthesis market.

Moreover, due to the presence of batteries and motors, they are likely to be heavy as compared with body-powered prostheses,and thus impede the motorized prosthesis market growth.

Access Exclusive Market Insights – Purchase Now!

Motorized Prosthesis Market: Key Players

Some of the market participants in the global motorized prosthesis market are Advanced Arm Dynamics, Bionic Prosthetics and Orthotics, BionX Medical Technologies, Inc., Faulhaber Group, Freedom Innovations, LLC, Mobius Bionics LLC, Össur hf., Otto Bock HealthCare GmbH, Sensars Neuroprosthetics, and Touch Bionics Inc.

Key Segments :

By Target Population:

Pediatric
Adult

By End-User:

Optics and Hospitals
Orthopedic Clinics
Trauma Centers

By Region:

North America
Latin America
Western Europe
Eastern Europe
Asia-Pacific
Japan
Middle East and Africa

About Future Market Insights (FMI)

Contact Us: